Successful induction of sclerostin in human-derived fibroblasts by 4 transcription factors and its regulation by parathyroid hormone,hypoxia, and prostaglandin E2 |
| |
| Affiliation: | 1. Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan;2. First Department of Oral and Maxillofacial Surgery, Osaka University Graduate School of Dentistry, Osaka 565-0871, Japan;3. DNA-chip Development Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan;4. Department of Pediatrics, JCHO Osaka Hospital, Osaka 553-0003, Japan;5. Department of Bone and Mineral Research, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka 594-1101, Japan;1. Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, MA, United States;2. Department of Orthopedic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, United States;1. Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, United States;2. Department of Biomedical Engineering, Indiana University-Purdue University at Indianapolis, IN, United States;3. Department of Anatomy and Cell Biology, Indiana University School of Medicine, IN, United States;4. Roudebush Veterans Administration Medical Center, Indianapolis, IN, United States;5. Department of Orthopaedic Surgery, Indiana University School of Medicine, IN, United States;1. Department of Orthopaedics, New Jersey Medical School, Rutgers University, 205 S. Orange Avenue, Newark, NJ 07103, USA;2. Department of Biomedical Engineering, New Jersey Institute of Technology, 323 Martin Luther King, Jr. Boulevard, Newark, NJ 07102, USA;3. Department of Anatomy and Cell Biology, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, IN 46202, USA;1. Research Promotion, Ono Pharmaceutical Co., Ltd., Shimamoto, Osaka 618-8585, Japan;2. Discovery Research Laboratories, Ono Pharmaceutical Co., Ltd., Shimamoto, Osaka 618-8585, Japan;3. Department of Orthopedic Surgery, Kagawa University Faculty of Medicine, Mikicho, Kagawa 761-0793, Japan |
| |
| Abstract: | Sclerostin, coded by SOST, is a secretory protein that is specifically expressed in osteocytes and suppresses osteogenesis by inhibiting WNT signaling. The regulatory mechanism underlying SOST expression remains unclear mainly due to the absence of an adequate human cell model. Thus, we herein attempted to establish a cell model of human dermal fibroblasts in order to investigate the functions of sclerostin. We selected 20 candidate transcription factors (TFs) that induce SOST expression by analyzing gene expression patterns in the human sarcoma cell line, SaOS-2, between differentiation and maintenance cultures using microarrays. An effective set of TFs to induce SOST expression was sought by their viral transduction into fibroblasts, and a combination of four TFs: ATF3, KLF4, PAX4, and SP7, was identified as the most effective inducer of SOST expression. Quantitative PCR demonstrated that the expression levels of SOST in fibroblasts treated with the 4 TFs were 199- and 1439-fold higher than those of the control after 1-week and 4-week cultures, respectively. The level of sclerostin in the conditioned medium, as determined by ELISA, was 21.2 pmol/l 4 weeks after the transduction of the 4 TFs. Interestingly, the production of Dickkopf1 (DKK1), another secreted inhibitor of WNT signaling, was also increased by transduction of these 4 TFs. Parathyroid hormone (PTH) significantly suppressed the induced SOST by 38% and sclerostin by 82% that of the vehicle. Hypoxia increased the induced SOST by 62% that of normoxia. Furthermore, prostaglandin E2 (PGE2) increased SOST expression levels to 16-fold those of the vehicle. In conclusion, the efficient induction of SOST expression and sclerostin production was achieved in human dermal fibroblasts by the transduction of ATF3, KLF4, PAX4, and SP7, and the induced SOST and sclerostin were regulated by PTH, hypoxia, and PGE2. This model may contribute to elucidating the regulatory mechanisms underlying SOST expression and advancing drug development for metabolic bone diseases. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
